numerical rating scale - Savikalpa Academy

There’s no notification yet!

Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain

Context
Prior Phase 2/3 studies found that cannabinoids might provide adjunctive analgesia in advanced cancer patients with uncontrolled pain.

Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies

Background: Opioids are critical for managing cancer pain, but may provide inadequate relief and/or unacceptable side effects in some cases.

Objective: To assess the analgesic efficacy of adjunctive Sativex (Δ9-tetrahydrocannabinol (27 mg/mL): cannabidiol (25 mg/mL)) in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy.

DISCLAIMER – All individuals accessing this site undertake full responsibility for their own assessment of the accuracy/relevance of any and all content found herein. The content found on this site is not intended to serve as a substitute for medical advice/diagnosis/treatment from a qualified and licensed health care provider. This information should also in no way be misconstrued as professional legal advice regarding legislative, regulatory or any other matters. Individuals should always seek out the guidance of fully qualified professionals.

Sign up for our Newsletter

MIGRAINE

INSOMNIA

HEADACHES

CANCER PAIN

ENDOMETRIOSIS

ARTHRITIS

PARKINSON'S

MULTIPLE SCLEROSIS

PSORIASIS

PELVIC PAIN

IBD

STRESS & ANXIETY

Sign up for our Newsletter

Filter